#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-8	Abnormal	_
1-2	9-23	Frontostriatal	_
1-3	24-32	Activity	_
1-4	33-39	During	_
1-5	40-50	Unexpected	_
1-6	51-57	Reward	_
1-7	58-65	Receipt	_
1-8	66-68	in	_
1-9	69-79	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
1-10	80-83	and	_
1-11	84-97	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	98-99	:	_
1-13	100-112	Relationship	_
1-14	113-115	to	_
1-15	116-125	Anhedonia	_
1-16	126-137	Alterations	_
1-17	138-140	in	_
1-18	141-147	reward	_
1-19	148-157	processes	_
1-20	158-161	may	_
1-21	162-170	underlie	_
1-22	171-183	motivational	_
1-23	184-187	and	_
1-24	188-197	anhedonic	_
1-25	198-206	symptoms	_
1-26	207-209	in	_
1-27	210-220	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
1-28	221-224	and	_
1-29	225-238	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	239-240	.	_

2-1	241-248	However	_
2-2	249-251	it	_
2-3	252-259	remains	_
2-4	260-267	unclear	_
2-5	268-275	whether	_
2-6	276-281	these	_
2-7	282-293	alterations	_
2-8	294-297	are	_
2-9	298-315	disorder-specific	_
2-10	316-318	or	_
2-11	319-325	shared	_
2-12	326-327	,	_
2-13	328-331	and	_
2-14	332-339	whether	_
2-15	340-344	they	_
2-16	345-352	clearly	_
2-17	353-359	relate	_
2-18	360-362	to	_
2-19	363-370	symptom	_
2-20	371-381	generation	_
2-21	382-384	or	_
2-22	385-388	not	_
2-23	389-390	.	_

3-1	391-393	We	_
3-2	394-401	studied	_
3-3	402-407	brain	_
3-4	408-417	responses	_
3-5	418-420	to	_
3-6	421-431	unexpected	_
3-7	432-439	rewards	_
3-8	440-446	during	_
3-9	447-448	a	_
3-10	449-458	simulated	_
3-11	459-471	slot-machine	_
3-12	472-476	game	http://maven.renci.org/NeuroBridge/neurobridge#GamingDisorder
3-13	477-479	in	_
3-14	480-482	24	_
3-15	483-491	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression
3-16	492-496	with	http://maven.renci.org/NeuroBridge/neurobridge#Depression
3-17	497-507	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
3-18	508-509	,	_
3-19	510-512	21	_
3-20	513-521	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-21	522-526	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-22	527-540	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-23	541-542	,	_
3-24	543-546	and	_
3-25	547-549	21	_
3-26	550-557	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-27	558-566	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-28	567-572	using	_
3-29	573-583	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-30	584-592	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-31	593-602	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-32	603-610	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-33	611-612	.	_

4-1	613-615	We	_
4-2	616-628	investigated	_
4-3	629-642	relationships	_
4-4	643-650	between	_
4-5	651-656	brain	_
4-6	657-667	activation	_
4-7	668-669	,	_
4-8	670-682	task-related	_
4-9	683-693	motivation	_
4-10	694-695	,	_
4-11	696-699	and	_
4-12	700-713	questionnaire	_
4-13	714-719	rated	_
4-14	720-729	anhedonia	_
4-15	730-731	.	_

5-1	732-737	There	_
5-2	738-741	was	_
5-3	742-749	reduced	_
5-4	750-760	activation	_
5-5	761-763	in	_
5-6	764-767	the	_
5-7	768-781	orbitofrontal	_
5-8	782-788	cortex	_
5-9	789-790	,	_
5-10	791-798	ventral	_
5-11	799-807	striatum	_
5-12	808-809	,	_
5-13	810-818	inferior	_
5-14	819-827	temporal	_
5-15	828-833	gyrus	_
5-16	834-835	,	_
5-17	836-839	and	_
5-18	840-849	occipital	_
5-19	850-856	cortex	_
5-20	857-859	in	_
5-21	860-864	both	_
5-22	865-875	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
5-23	876-879	and	_
5-24	880-893	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-25	894-896	in	_
5-26	897-907	comparison	_
5-27	908-912	with	_
5-28	913-920	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-29	921-933	participants	_
5-30	934-940	during	_
5-31	941-948	receipt	_
5-32	949-951	of	_
5-33	952-962	unexpected	_
5-34	963-969	reward	_
5-35	970-971	.	_

6-1	972-974	In	_
6-2	975-978	the	_
6-3	979-985	medial	_
6-4	986-996	prefrontal	_
6-5	997-1003	cortex	_
6-6	1004-1008	both	_
6-7	1009-1016	patient	_
6-8	1017-1023	groups	_
6-9	1024-1030	showed	_
6-10	1031-1038	reduced	_
6-11	1039-1049	activation	_
6-12	1050-1051	,	_
6-13	1052-1056	with	_
6-14	1057-1067	activation	_
6-15	1068-1081	significantly	_
6-16	1082-1086	more	_
6-17	1087-1095	abnormal	_
6-18	1096-1098	in	_
6-19	1099-1112	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-20	1113-1117	than	_
6-21	1118-1128	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
6-22	1129-1130	.	_

7-1	1131-1139	Anterior	_
7-2	1140-1149	cingulate	_
7-3	1150-1153	and	_
7-4	1154-1160	medial	_
7-5	1161-1168	frontal	_
7-6	1169-1177	cortical	_
7-7	1178-1188	activation	_
7-8	1189-1198	predicted	_
7-9	1199-1211	task-related	_
7-10	1212-1222	motivation	_
7-11	1223-1224	,	_
7-12	1225-1230	which	_
7-13	1231-1233	in	_
7-14	1234-1238	turn	_
7-15	1239-1248	predicted	_
7-16	1249-1258	anhedonia	_
7-17	1259-1267	severity	_
7-18	1268-1270	in	_
7-19	1271-1284	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-20	1285-1286	.	_

8-1	1287-1290	Our	_
8-2	1291-1299	findings	_
8-3	1300-1307	provide	_
8-4	1308-1316	evidence	_
8-5	1317-1320	for	_
8-6	1321-1332	overlapping	_
8-7	1333-1345	hypofunction	_
8-8	1346-1348	in	_
8-9	1349-1356	ventral	_
8-10	1357-1365	striatal	_
8-11	1366-1369	and	_
8-12	1370-1383	orbitofrontal	_
8-13	1384-1391	regions	_
8-14	1392-1394	in	_
8-15	1395-1405	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
8-16	1406-1409	and	_
8-17	1410-1423	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-18	1424-1430	during	_
8-19	1431-1441	unexpected	_
8-20	1442-1448	reward	_
8-21	1449-1456	receipt	_
8-22	1457-1458	,	_
8-23	1459-1462	and	_
8-24	1463-1466	for	_
8-25	1467-1468	a	_
8-26	1469-1481	relationship	_
8-27	1482-1489	between	_
8-28	1490-1500	unexpected	_
8-29	1501-1507	reward	_
8-30	1508-1518	processing	_
8-31	1519-1521	in	_
8-32	1522-1525	the	_
8-33	1526-1532	medial	_
8-34	1533-1543	prefrontal	_
8-35	1544-1550	cortex	_
8-36	1551-1554	and	_
8-37	1555-1558	the	_
8-38	1559-1569	generation	_
8-39	1570-1572	of	_
8-40	1573-1585	motivational	_
8-41	1586-1592	states	_
8-42	1593-1594	.	_

9-1	1595-1604	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	1605-1608	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	1609-1616	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-4	1617-1629	Participants	_
9-5	1630-1633	The	_
9-6	1634-1639	study	_
9-7	1640-1643	was	_
9-8	1644-1652	approved	_
9-9	1653-1655	by	_
9-10	1656-1659	the	_
9-11	1660-1674	Cambridgeshire	_
9-12	1675-1676	3	_
9-13	1677-1685	National	_
9-14	1686-1692	Health	_
9-15	1693-1700	Service	_
9-16	1701-1709	research	_
9-17	1710-1716	ethics	_
9-18	1717-1726	committee	_
9-19	1727-1728	.	_

10-1	1729-1736	Written	_
10-2	1737-1745	informed	_
10-3	1746-1753	consent	_
10-4	1754-1757	was	_
10-5	1758-1766	obtained	_
10-6	1767-1771	from	_
10-7	1772-1775	all	_
10-8	1776-1788	participants	_
10-9	1789-1790	.	_

11-1	1791-1801	Twenty-one	_
11-2	1802-1808	people	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-3	1809-1813	with	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-4	1814-1820	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-5	1821-1834	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-6	1835-1836	,	_
11-7	1837-1839	24	_
11-8	1840-1846	people	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-9	1847-1851	with	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-10	1852-1858	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-11	1859-1864	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-12	1865-1875	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-13	1876-1884	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-14	1885-1886	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-15	1887-1890	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-16	1891-1892	)	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
11-17	1893-1894	,	_
11-18	1895-1898	and	_
11-19	1899-1901	21	_
11-20	1902-1909	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-21	1910-1920	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-22	1921-1925	took	_
11-23	1926-1930	part	_
11-24	1931-1933	in	_
11-25	1934-1937	the	_
11-26	1938-1943	study	_
11-27	1944-1945	(	_
11-28	1946-1951	Table	_
11-29	1952-1953	1	_
11-30	1954-1955	)	_
11-31	1956-1957	.	_

12-1	1958-1961	All	_
12-2	1962-1975	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-3	1976-1988	participants	_
12-4	1989-1993	were	_
12-5	1994-2000	taking	_
12-6	2001-2014	antipsychotic	_
12-7	2015-2025	medication	_
12-8	2026-2027	;	_
12-9	2028-2033	eight	_
12-10	2034-2038	were	_
12-11	2039-2051	additionally	_
12-12	2052-2058	taking	_
12-13	2059-2073	antidepressant	_
12-14	2074-2084	medication	_
12-15	2085-2086	.	_

13-1	2087-2095	Thirteen	_
13-2	2096-2098	of	_
13-3	2099-2102	the	_
13-4	2103-2105	24	_
13-5	2106-2116	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
13-6	2117-2129	participants	http://maven.renci.org/NeuroBridge/neurobridge#Depression
13-7	2130-2134	were	_
13-8	2135-2141	taking	_
13-9	2142-2156	antidepressant	_
13-10	2157-2167	medication	_
13-11	2168-2169	,	_
13-12	2170-2172	of	_
13-13	2173-2177	whom	_
13-14	2178-2182	four	_
13-15	2183-2187	were	_
13-16	2188-2200	additionally	_
13-17	2201-2207	taking	_
13-18	2208-2221	antipsychotic	_
13-19	2222-2232	medication	_
13-20	2233-2234	;	_
13-21	2235-2245	medication	_
13-22	2246-2248	is	_
13-23	2249-2258	described	_
13-24	2259-2261	in	_
13-25	2262-2267	Table	_
13-26	2268-2269	1	_
13-27	2270-2273	and	_
13-28	2274-2276	in	_
13-29	2277-2284	further	_
13-30	2285-2291	detail	_
13-31	2292-2294	in	_
13-32	2295-2308	Supplementary	_
13-33	2309-2317	Material	_
13-34	2318-2319	.	_

14-1	2320-2329	Inclusion	_
14-2	2330-2338	criteria	_
14-3	2339-2343	were	_
14-4	2344-2346	an	_
14-5	2347-2350	age	_
14-6	2351-2358	between	_
14-7	2359-2361	18	_
14-8	2362-2365	and	_
14-9	2366-2368	65	_
14-10	2369-2372	and	_
14-11	2373-2381	adequate	_
14-12	2382-2393	proficiency	_
14-13	2394-2396	in	_
14-14	2397-2404	English	_
14-15	2405-2406	.	_

15-1	2407-2416	Exclusion	_
15-2	2417-2425	criteria	_
15-3	2426-2430	were	_
15-4	2431-2438	history	_
15-5	2439-2441	of	_
15-6	2442-2454	neurological	_
15-7	2455-2463	disorder	_
15-8	2464-2465	,	_
15-9	2466-2474	physical	_
15-10	2475-2482	illness	_
15-11	2483-2484	,	_
15-12	2485-2495	dependence	_
15-13	2496-2498	on	_
15-14	2499-2506	alcohol	_
15-15	2507-2509	or	_
15-16	2510-2522	recreational	_
15-17	2523-2528	drugs	_
15-18	2529-2530	,	_
15-19	2531-2534	and	_
15-20	2535-2538	any	_
15-21	2539-2555	contraindication	_
15-22	2556-2559	for	_
15-23	2560-2563	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-24	2564-2572	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-25	2573-2574	.	_

16-1	2575-2576	A	_
16-2	2577-2589	first-degree	_
16-3	2590-2596	family	_
16-4	2597-2604	history	_
16-5	2605-2607	of	_
16-6	2608-2621	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-7	2622-2624	or	_
16-8	2625-2632	bipolar	_
16-9	2633-2641	disorder	_
16-10	2642-2645	was	_
16-11	2646-2648	an	_
16-12	2649-2659	additional	_
16-13	2660-2669	exclusion	_
16-14	2670-2679	criterion	_
16-15	2680-2682	in	_
16-16	2683-2686	the	_
16-17	2687-2697	depression	_
16-18	2698-2701	and	_
16-19	2702-2709	control	_
16-20	2710-2716	groups	_
16-21	2717-2718	.	_

17-1	2719-2722	All	_
17-2	2723-2735	participants	_
17-3	2736-2740	with	_
17-4	2741-2751	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
17-5	2752-2754	or	_
17-6	2755-2768	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-7	2769-2781	subjectively	_
17-8	2782-2790	endorsed	_
17-9	2791-2792	a	_
17-10	2793-2799	degree	_
17-11	2800-2802	of	_
17-12	2803-2807	loss	_
17-13	2808-2810	of	_
17-14	2811-2819	interest	_
17-15	2820-2822	or	_
17-16	2823-2831	pleasure	_
17-17	2832-2833	.	_

18-1	2834-2843	Anhedonia	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
18-2	2844-2854	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
18-3	2855-2857	To	_
18-4	2858-2864	assess	_
18-5	2865-2874	anhedonia	_
18-6	2875-2877	we	_
18-7	2878-2882	used	_
18-8	2883-2886	the	_
18-9	2887-2893	Snaith	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-10	2894-2902	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-11	2903-2911	Pleasure	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-12	2912-2917	Scale	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-13	2918-2919	(	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-14	2920-2925	SHAPS	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-15	2926-2927	)	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
18-16	2928-2929	,	_
18-17	2930-2931	a	_
18-18	2932-2941	validated	_
18-19	2942-2953	self-report	_
18-20	2954-2961	measure	_
18-21	2962-2963	.	_

19-1	2964-2968	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-2	2969-2973	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
19-3	2974-2985	Description	_
19-4	2986-2989	The	_
19-5	2990-2994	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
19-6	2995-3003	involved	_
19-7	3004-3011	playing	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
19-8	3012-3013	a	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalSymptomRating
19-9	3014-3026	computerized	_
19-10	3027-3034	version	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionInstrument
19-11	3035-3037	of	_
19-12	3038-3039	a	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
19-13	3040-3052	slot-machine	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
19-14	3053-3057	game	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
19-15	3058-3059	;	_
19-16	3060-3072	participants	_
19-17	3073-3077	view	_
19-18	3078-3081	two	_
19-19	3082-3087	reels	_
19-20	3088-3090	of	_
19-21	3091-3092	a	_
19-22	3093-3109	slot-machine/one	_
19-23	3110-3113	arm	_
19-24	3114-3120	bandit	_
19-25	3121-3125	game	_
19-26	3126-3127	,	_
19-27	3128-3133	where	_
19-28	3134-3137	the	_
19-29	3138-3142	left	_
19-30	3143-3147	hand	_
19-31	3148-3152	reel	_
19-32	3153-3155	is	_
19-33	3156-3166	stationary	_
19-34	3167-3170	and	_
19-35	3171-3174	the	_
19-36	3175-3180	right	_
19-37	3181-3185	hand	_
19-38	3186-3190	reel	_
19-39	3191-3196	spins	_
19-40	3197-3202	until	_
19-41	3203-3205	it	_
19-42	3206-3211	stops	_
19-43	3212-3213	(	_
19-44	3214-3220	Figure	_
19-45	3221-3222	1	_
19-46	3223-3224	)	_
19-47	3225-3226	.	_

20-1	3227-3229	If	_
20-2	3230-3233	the	_
20-3	3234-3237	two	_
20-4	3238-3243	icons	_
20-5	3244-3246	in	_
20-6	3247-3250	the	_
20-7	3251-3257	center	_
20-8	3258-3260	of	_
20-9	3261-3265	view	_
20-10	3266-3271	match	_
20-11	3272-3273	,	_
20-12	3274-3279	there	_
20-13	3280-3282	is	_
20-14	3283-3284	a	_
20-15	3285-3294	financial	_
20-16	3295-3301	reward	_
20-17	3302-3304	of	_
20-18	3305-3307	50	_
20-19	3308-3313	pence	_
20-20	3314-3315	.	_

21-1	3316-3328	Participants	_
21-2	3329-3332	win	_
21-3	3333-3335	on	_
21-4	3336-3338	an	_
21-5	3339-3346	average	_
21-6	3347-3350	one	_
21-7	3351-3353	in	_
21-8	3354-3357	six	_
21-9	3358-3364	trials	_
21-10	3365-3366	,	_
21-11	3367-3373	making	_
21-12	3374-3381	rewards	_
21-13	3382-3392	unexpected	_
21-14	3393-3395	in	_
21-15	3396-3400	this	_
21-16	3401-3405	game	_
21-17	3406-3407	.	_

22-1	3408-3419	Furthermore	_
22-2	3420-3421	,	_
22-3	3422-3425	the	_
22-4	3426-3434	duration	_
22-5	3435-3437	of	_
22-6	3438-3441	the	_
22-7	3442-3450	spinning	_
22-8	3451-3453	of	_
22-9	3454-3457	the	_
22-10	3458-3463	wheel	_
22-11	3464-3466	is	_
22-12	3467-3475	variable	_
22-13	3476-3478	in	_
22-14	3479-3483	this	_
22-15	3484-3488	task	_
22-16	3489-3490	(	_
22-17	3491-3496	delay	_
22-18	3497-3503	varies	_
22-19	3504-3511	between	_
22-20	3512-3515	2.8	_
22-21	3516-3519	and	_
22-22	3520-3521	6	_
22-23	3522-3523	s	_
22-24	3524-3525	)	_
22-25	3526-3527	,	_
22-26	3528-3530	so	_
22-27	3531-3534	the	_
22-28	3535-3542	precise	_
22-29	3543-3549	timing	_
22-30	3550-3552	of	_
22-31	3553-3556	the	_
22-32	3557-3564	outcome	_
22-33	3565-3567	is	_
22-34	3568-3572	also	_
22-35	3573-3576	not	_
22-36	3577-3588	predictable	_
22-37	3589-3590	.	_

23-1	3591-3594	The	_
23-2	3595-3599	game	_
23-3	3600-3609	consisted	_
23-4	3610-3612	of	_
23-5	3613-3616	two	_
23-6	3617-3621	runs	_
23-7	3622-3624	of	_
23-8	3625-3627	60	_
23-9	3628-3634	trials	_
23-10	3635-3636	,	_
23-11	3637-3641	each	_
23-12	3642-3645	run	_
23-13	3646-3653	lasting	_
23-14	3654-3657	~20	_
23-15	3658-3661	min	_
23-16	3662-3663	,	_
23-17	3664-3667	and	_
23-18	3668-3671	has	_
23-19	3672-3676	been	_
23-20	3677-3687	previously	_
23-21	3688-3697	described	_
23-22	3698-3699	.	_

24-1	3700-3702	On	_
24-2	3703-3705	50	_
24-3	3706-3707	%	_
24-4	3708-3710	of	_
24-5	3711-3717	trials	_
24-6	3718-3719	,	_
24-7	3720-3723	the	_
24-8	3724-3735	participant	_
24-9	3736-3743	selects	_
24-10	3744-3747	the	_
24-11	3748-3749	‘	_
24-12	3750-3754	play	_
24-13	3755-3764	icon'—the	_
24-14	3765-3770	image	_
24-15	3771-3773	in	_
24-16	3774-3777	the	_
24-17	3778-3784	center	_
24-18	3785-3787	of	_
24-19	3788-3791	the	_
24-20	3792-3796	left	_
24-21	3797-3801	hand	_
24-22	3802-3809	reel—by	_
24-23	3810-3818	rotating	_
24-24	3819-3822	the	_
24-25	3823-3827	reel	_
24-26	3828-3830	to	_
24-27	3831-3834	the	_
24-28	3835-3839	icon	_
24-29	3840-3842	of	_
24-30	3843-3848	their	_
24-31	3849-3855	choice	_
24-32	3856-3857	.	_

25-1	3858-3860	In	_
25-2	3861-3864	the	_
25-3	3865-3870	other	_
25-4	3871-3873	50	_
25-5	3874-3875	%	_
25-6	3876-3878	of	_
25-7	3879-3885	trials	_
25-8	3886-3887	(	_
25-9	3888-3904	pseudorandomised	_
25-10	3905-3917	distribution	_
25-11	3918-3919	)	_
25-12	3920-3921	,	_
25-13	3922-3925	the	_
25-14	3926-3934	computer	_
25-15	3935-3942	selects	_
25-16	3943-3946	the	_
25-17	3947-3948	‘	_
25-18	3949-3953	play	_
25-19	3954-3958	icon	_
25-20	3959-3960	'	_
25-21	3961-3963	on	_
25-22	3964-3969	these	_
25-23	3970-3976	trials	_
25-24	3977-3980	the	_
25-25	3981-3992	participant	_
25-26	3993-3995	is	_
25-27	3996-4004	required	_
25-28	4005-4007	to	_
25-29	4008-4015	confirm	_
25-30	4016-4020	with	_
25-31	4021-4022	a	_
25-32	4023-4029	button	_
25-33	4030-4035	press	_
25-34	4036-4040	that	_
25-35	4041-4047	he/she	_
25-36	4048-4051	has	_
25-37	4052-4057	noted	_
25-38	4058-4061	the	_
25-39	4062-4070	computer	_
25-40	4071-4077	choice	_
25-41	4078-4079	.	_

26-1	4080-4085	After	_
26-2	4086-4090	this	_
26-3	4091-4100	selection	_
26-4	4101-4106	phase	_
26-5	4107-4110	the	_
26-6	4111-4116	right	_
26-7	4117-4121	hand	_
26-8	4122-4126	reel	_
26-9	4127-4133	starts	_
26-10	4134-4136	to	_
26-11	4137-4141	spin	_
26-12	4142-4143	.	_

27-1	4144-4147	The	_
27-2	4148-4157	selection	_
27-3	4158-4163	phase	_
27-4	4164-4169	lasts	_
27-5	4170-4171	5	_
27-6	4172-4173	s	_
27-7	4174-4175	,	_
27-8	4176-4184	followed	_
27-9	4185-4187	by	_
27-10	4188-4189	a	_
27-11	4190-4198	variable	_
27-12	4199-4204	delay	_
27-13	4205-4210	stage	_
27-14	4211-4217	whilst	_
27-15	4218-4221	the	_
27-16	4222-4228	second	_
27-17	4229-4233	reel	_
27-18	4234-4239	spins	_
27-19	4240-4243	and	_
27-20	4244-4249	comes	_
27-21	4250-4252	to	_
27-22	4253-4254	a	_
27-23	4255-4259	stop	_
27-24	4260-4261	,	_
27-25	4262-4270	followed	_
27-26	4271-4273	by	_
27-27	4274-4276	an	_
27-28	4277-4284	outcome	_
27-29	4285-4290	phase	_
27-30	4291-4293	of	_
27-31	4294-4295	4	_
27-32	4296-4297	s	_
27-33	4298-4303	where	_
27-34	4304-4307	the	_
27-35	4308-4314	reward	_
27-36	4315-4317	is	_
27-37	4318-4327	presented	_
27-38	4328-4329	:	_
27-39	4330-4331	‘	_
27-40	4332-4337	£0.50	_
27-41	4338-4341	win	_
27-42	4342-4343	!	_
27-43	4344-4345	'	_

28-1	4346-4347	(	_
28-2	4348-4350	if	_
28-3	4351-4354	the	_
28-4	4355-4360	icons	_
28-5	4361-4363	on	_
28-6	4364-4367	the	_
28-7	4368-4375	payline	_
28-8	4376-4378	of	_
28-9	4379-4382	the	_
28-10	4383-4386	two	_
28-11	4387-4392	reels	_
28-12	4393-4398	match	_
28-13	4399-4400	)	_
28-14	4401-4403	or	_
28-15	4404-4405	‘	_
28-16	4406-4408	No	_
28-17	4409-4412	win	_
28-18	4413-4414	'	_
28-19	4415-4416	(	_
28-20	4417-4419	if	_
28-21	4420-4424	they	_
28-22	4425-4427	do	_
28-23	4428-4431	not	_
28-24	4432-4437	match	_
28-25	4438-4439	)	_
28-26	4440-4441	.	_

29-1	4442-4444	If	_
29-2	4445-4467	selection/confirmation	_
29-3	4468-4471	did	_
29-4	4472-4475	not	_
29-5	4476-4481	occur	_
29-6	4482-4488	within	_
29-7	4489-4490	5	_
29-8	4491-4492	s	_
29-9	4493-4494	,	_
29-10	4495-4496	‘	_
29-11	4497-4500	too	_
29-12	4501-4505	late	_
29-13	4506-4507	'	_
29-14	4508-4511	was	_
29-15	4512-4521	presented	_
29-16	4522-4524	on	_
29-17	4525-4528	the	_
29-18	4529-4535	screen	_
29-19	4536-4539	and	_
29-20	4540-4543	the	_
29-21	4544-4548	task	_
29-22	4549-4554	moved	_
29-23	4555-4557	on	_
29-24	4558-4560	to	_
29-25	4561-4564	the	_
29-26	4565-4569	next	_
29-27	4570-4575	trial	_
29-28	4576-4577	.	_

30-1	4578-4580	At	_
30-2	4581-4584	the	_
30-3	4585-4588	end	_
30-4	4589-4591	of	_
30-5	4592-4596	each	_
30-6	4597-4602	trial	_
30-7	4603-4604	,	_
30-8	4605-4610	there	_
30-9	4611-4614	was	_
30-10	4615-4616	a	_
30-11	4617-4625	variable	_
30-12	4626-4637	inter-trial	_
30-13	4638-4646	interval	_
30-14	4647-4649	of	_
30-15	4650-4657	between	_
30-16	4658-4659	2	_
30-17	4660-4663	and	_
30-18	4664-4665	7	_
30-19	4666-4667	s	_
30-20	4668-4676	duration	_
30-21	4677-4678	.	_

31-1	4679-4691	Participants	_
31-2	4692-4696	were	_
31-3	4697-4701	told	_
31-4	4702-4706	that	_
31-5	4707-4711	they	_
31-6	4712-4717	would	_
31-7	4718-4720	be	_
31-8	4721-4726	given	_
31-9	4727-4730	any	_
31-10	4731-4736	money	_
31-11	4737-4741	they	_
31-12	4742-4745	won	_
31-13	4746-4748	at	_
31-14	4749-4752	the	_
31-15	4753-4756	end	_
31-16	4757-4759	of	_
31-17	4760-4763	the	_
31-18	4764-4774	experiment	_
31-19	4775-4776	.	_

32-1	4777-4789	Task-related	_
32-2	4790-4798	pleasure	_
32-3	4799-4802	and	_
32-4	4803-4813	motivation	_
32-5	4814-4825	Immediately	_
32-6	4826-4831	after	_
32-7	4832-4835	the	_
32-8	4836-4840	scan	_
32-9	4841-4848	session	_
32-10	4849-4852	the	_
32-11	4853-4865	participants	_
32-12	4866-4874	answered	_
32-13	4875-4878	the	_
32-14	4879-4888	questions	_
32-15	4889-4890	,	_
32-16	4891-4892	‘	_
32-17	4893-4897	When	_
32-18	4898-4901	the	_
32-19	4902-4908	second	_
32-20	4909-4916	picture	_
32-21	4917-4924	matched	_
32-22	4925-4928	the	_
32-23	4929-4935	chosen	_
32-24	4936-4943	picture	_
32-25	4944-4947	you	_
32-26	4948-4951	won	_
32-27	4952-4957	money	_
32-28	4958-4959	.	_

33-1	4960-4963	How	_
33-2	4964-4968	much	_
33-3	4969-4972	did	_
33-4	4973-4976	you	_
33-5	4977-4981	like	_
33-6	4982-4985	the	_
33-7	4986-4993	feeling	_
33-8	4994-4996	of	_
33-9	4997-5004	winning	_
33-10	5005-5010	money	_
33-11	5011-5012	?	_
33-12	5013-5014	'	_

34-1	5015-5018	and	_
34-2	5019-5020	,	_
34-3	5021-5022	‘	_
34-4	5023-5027	When	_
34-5	5028-5031	the	_
34-6	5032-5038	second	_
34-7	5039-5046	picture	_
34-8	5047-5054	matched	_
34-9	5055-5058	the	_
34-10	5059-5065	chosen	_
34-11	5066-5073	picture	_
34-12	5074-5077	you	_
34-13	5078-5081	won	_
34-14	5082-5087	money	_
34-15	5088-5089	.	_

35-1	5090-5093	Did	_
35-2	5094-5098	this	_
35-3	5099-5103	make	_
35-4	5104-5107	you	_
35-5	5108-5112	want	_
35-6	5113-5115	to	_
35-7	5116-5120	play	_
35-8	5121-5125	more	_
35-9	5126-5127	?	_
35-10	5128-5129	'	_

36-1	5130-5133	The	_
36-2	5134-5141	answers	_
36-3	5142-5146	were	_
36-4	5147-5153	marked	_
36-5	5154-5156	on	_
36-6	5157-5158	a	_
36-7	5159-5165	visual	_
36-8	5166-5172	analog	_
36-9	5173-5178	scale	_
36-10	5179-5180	.	_

37-1	5181-5185	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-2	5186-5190	Data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-3	5191-5202	Acquisition	_
37-4	5203-5206	and	_
37-5	5207-5221	Pre-Processing	_
37-6	5222-5223	A	_
37-7	5224-5231	Siemens	_
37-8	5232-5236	Trio	_
37-9	5237-5240	Tim	_
37-10	5241-5250	operating	_
37-11	5251-5253	at	_
37-12	5254-5256	3T	_
37-13	5257-5260	was	_
37-14	5261-5265	used	_
37-15	5266-5268	to	_
37-16	5269-5276	collect	_
37-17	5277-5284	imaging	_
37-18	5285-5289	data	_
37-19	5290-5291	.	_

38-1	5292-5305	Gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-2	5306-5308	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-3	5309-5310	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-4	5311-5320	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-5	5321-5325	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-6	5326-5332	planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-7	5333-5339	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-8	5340-5349	depicting	_
38-9	5350-5354	BOLD	_
38-10	5355-5363	contrast	_
38-11	5364-5368	were	_
38-12	5369-5377	acquired	_
38-13	5378-5382	from	_
38-14	5383-5385	32	_
38-15	5386-5399	noncontiguous	_
38-16	5400-5407	oblique	_
38-17	5408-5413	axial	_
38-18	5414-5420	planes	_
38-19	5421-5423	to	_
38-20	5424-5432	minimize	_
38-21	5433-5439	signal	_
38-22	5440-5448	drop-out	_
38-23	5449-5451	in	_
38-24	5452-5459	ventral	_
38-25	5460-5467	regions	_
38-26	5468-5469	.	_

39-1	5470-5474	TR=2	_
39-2	5475-5476	s	_
39-3	5477-5478	;	_
39-4	5479-5483	echo	_
39-5	5484-5491	time=30	_
39-6	5492-5494	ms	_
39-7	5495-5496	;	_
39-8	5497-5501	flip	_
39-9	5502-5510	angle=78	_
39-10	5511-5512	;	_
39-11	5513-5518	voxel	_
39-12	5519-5528	size=3.14	_
39-13	5529-5530	×	_
39-14	5531-5535	3.14	_
39-15	5536-5537	×	_
39-16	5538-5542	3.75	_
39-17	5543-5546	mm3	_
39-18	5547-5548	,	_
39-19	5549-5555	matrix	_
39-20	5556-5560	size	_
39-21	5561-5563	64	_
39-22	5564-5565	×	_
39-23	5566-5568	64	_
39-24	5569-5570	;	_
39-25	5571-5580	bandwidth	_
39-26	5581-5585	2232	_
39-27	5586-5591	HZ/Px	_
39-28	5592-5593	.	_

40-1	5594-5595	A	_
40-2	5596-5611	high-resolution	_
40-3	5612-5623	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-4	5624-5641	three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-5	5642-5649	MP-RAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-6	5650-5660	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-7	5661-5666	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-8	5667-5670	was	_
40-9	5671-5675	also	_
40-10	5676-5684	acquired	_
40-11	5685-5688	for	_
40-12	5689-5692	use	_
40-13	5693-5695	in	_
40-14	5696-5703	spatial	_
40-15	5704-5717	normalization	_
40-16	5718-5720	of	_
40-17	5721-5724	the	_
40-18	5725-5728	EPI	_
40-19	5729-5735	series	_
40-20	5736-5737	.	_

41-1	5738-5745	Imaging	_
41-2	5746-5750	data	_
41-3	5751-5754	was	_
41-4	5755-5763	analyzed	_
41-5	5764-5769	using	_
41-6	5770-5773	FSL	_
41-7	5774-5782	software	_
41-8	5783-5784	(	_
41-9	5785-5790	FMRIB	_
41-10	5791-5793	's	_
41-11	5794-5802	Software	_
41-12	5803-5810	Library	_
41-13	5811-5812	,	_
41-14	5813-5835	www.fmrib.ox.ac.uk/fsl	_
41-15	5836-5837	)	_
41-16	5838-5839	.	_

42-1	5840-5843	See	_
42-2	5844-5857	Supplementary	_
42-3	5858-5866	Material	_
42-4	5867-5870	for	_
42-5	5871-5885	pre-processing	_
42-6	5886-5893	details	_
42-7	5894-5895	.	_

43-1	5896-5900	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
43-2	5901-5905	Data	_
43-3	5906-5914	Analysis	_
43-4	5915-5917	An	_
43-5	5918-5931	event-related	_
43-6	5932-5940	analysis	_
43-7	5941-5943	in	_
43-8	5944-5947	FSL	_
43-9	5948-5956	software	_
43-10	5957-5960	was	_
43-11	5961-5965	used	_
43-12	5966-5968	to	_
43-13	5969-5977	identify	_
43-14	5978-5984	neural	_
43-15	5985-5994	responses	_
43-16	5995-5997	at	_
43-17	5998-6001	the	_
43-18	6002-6006	time	_
43-19	6007-6009	of	_
43-20	6010-6013	the	_
43-21	6014-6024	unexpected	_
43-22	6025-6028	win	_
43-23	6029-6030	.	_

44-1	6031-6033	We	_
44-2	6034-6038	used	_
44-3	6039-6040	a	_
44-4	6041-6047	single	_
44-5	6048-6059	statistical	_
44-6	6060-6066	linear	_
44-7	6067-6077	regression	_
44-8	6078-6083	model	_
44-9	6084-6088	with	_
44-10	6089-6093	four	_
44-11	6094-6105	explanatory	_
44-12	6106-6115	variables	_
44-13	6116-6119	and	_
44-14	6120-6125	their	_
44-15	6126-6134	temporal	_
44-16	6135-6146	derivatives	_
44-17	6147-6148	:	_
44-18	6149-6150	(	_
44-19	6151-6152	a	_
44-20	6153-6154	)	_
44-21	6155-6167	anticipation	_
44-22	6168-6173	phase	_
44-23	6174-6175	(	_
44-24	6176-6179	the	_
44-25	6180-6188	duration	_
44-26	6189-6191	of	_
44-27	6192-6196	this	_
44-28	6197-6202	event	_
44-29	6203-6209	varied	_
44-30	6210-6217	between	_
44-31	6218-6221	2.8	_
44-32	6222-6225	and	_
44-33	6226-6227	6	_
44-34	6228-6229	s	_
44-35	6230-6232	on	_
44-36	6233-6242	different	_
44-37	6243-6249	trials	_
44-38	6250-6251	)	_
44-39	6252-6253	;	_
44-40	6254-6255	(	_
44-41	6256-6257	b	_
44-42	6258-6259	)	_
44-43	6260-6263	win	_
44-44	6264-6271	outcome	_
44-45	6272-6273	(	_
44-46	6274-6275	4	_
44-47	6276-6277	s	_
44-48	6278-6286	duration	_
44-49	6287-6288	,	_
44-50	6289-6291	20	_
44-51	6292-6298	events	_
44-52	6299-6301	in	_
44-53	6302-6307	total	_
44-54	6308-6309	)	_
44-55	6310-6311	;	_
44-56	6312-6313	(	_
44-57	6314-6315	c	_
44-58	6316-6317	)	_
44-59	6318-6327	near-miss	_
44-60	6328-6336	outcomes	_
44-61	6337-6338	(	_
44-62	6339-6340	4	_
44-63	6341-6342	s	_
44-64	6343-6351	duration	_
44-65	6352-6353	,	_
44-66	6354-6356	40	_
44-67	6357-6363	events	_
44-68	6364-6366	in	_
44-69	6367-6372	total	_
44-70	6373-6374	)	_
44-71	6375-6376	;	_
44-72	6377-6378	(	_
44-73	6379-6380	d	_
44-74	6381-6382	)	_
44-75	6383-6392	full-miss	_
44-76	6393-6401	outcomes	_
44-77	6402-6403	(	_
44-78	6404-6405	4	_
44-79	6406-6407	s	_
44-80	6408-6416	duration	_
44-81	6417-6418	,	_
44-82	6419-6421	60	_
44-83	6422-6428	events	_
44-84	6429-6431	in	_
44-85	6432-6437	total	_
44-86	6438-6439	)	_
44-87	6440-6441	.	_

45-1	6442-6443	A	_
45-2	6444-6453	near-miss	_
45-3	6454-6461	outcome	_
45-4	6462-6464	is	_
45-5	6465-6470	where	_
45-6	6471-6474	the	_
45-7	6475-6479	play	_
45-8	6480-6484	icon	_
45-9	6485-6493	finishes	_
45-10	6494-6502	adjacent	_
45-11	6503-6505	to	_
45-12	6506-6507	,	_
45-13	6508-6511	but	_
45-14	6512-6515	not	_
45-15	6516-6518	on	_
45-16	6519-6520	,	_
45-17	6521-6524	the	_
45-18	6525-6532	payline	_
45-19	6533-6534	;	_
45-20	6535-6544	near-miss	_
45-21	6545-6553	outcomes	_
45-22	6554-6558	have	_
45-23	6559-6563	been	_
45-24	6564-6569	shown	_
45-25	6570-6572	to	_
45-26	6573-6578	evoke	_
45-27	6579-6585	neural	_
45-28	6586-6595	responses	_
45-29	6596-6605	different	_
45-30	6606-6608	to	_
45-31	6609-6614	other	_
45-32	6615-6621	misses	_
45-33	6622-6623	.	_

46-1	6624-6632	Movement	_
46-2	6633-6643	parameters	_
46-3	6644-6648	from	_
46-4	6649-6652	the	_
46-5	6653-6664	realignment	_
46-6	6665-6669	step	_
46-7	6670-6674	were	_
46-8	6675-6679	also	_
46-9	6680-6688	included	_
46-10	6689-6691	in	_
46-11	6692-6695	the	_
46-12	6696-6707	first-level	_
46-13	6708-6713	model	_
46-14	6714-6715	.	_

47-1	6716-6718	As	_
47-2	6719-6722	our	_
47-3	6723-6733	hypotheses	_
47-4	6734-6743	concerned	_
47-5	6744-6749	brain	_
47-6	6750-6760	activation	_
47-7	6761-6763	in	_
47-8	6764-6772	response	_
47-9	6773-6775	to	_
47-10	6776-6786	unexpected	_
47-11	6787-6793	reward	_
47-12	6794-6795	,	_
47-13	6796-6798	an	_
47-14	6799-6800	‘	_
47-15	6801-6811	unexpected	_
47-16	6812-6818	reward	_
47-17	6819-6826	receipt	_
47-18	6827-6828	'	_
47-19	6829-6837	contrast	_
47-20	6838-6841	was	_
47-21	6842-6854	investigated	_
47-22	6855-6856	,	_
47-23	6857-6863	formed	_
47-24	6864-6866	by	_
47-25	6867-6870	the	_
47-26	6871-6879	contrast	_
47-27	6880-6882	of	_
47-28	6883-6886	win	_
47-29	6887-6895	outcomes	_
47-30	6896-6898	vs	_
47-31	6899-6908	full-miss	_
47-32	6909-6917	outcomes	_
47-33	6918-6919	.	_

48-1	6920-6924	This	_
48-2	6925-6933	contrast	_
48-3	6934-6937	was	_
48-4	6938-6946	computed	_
48-5	6947-6949	at	_
48-6	6950-6953	the	_
48-7	6954-6972	single-participant	_
48-8	6973-6978	level	_
48-9	6979-6982	and	_
48-10	6983-6986	the	_
48-11	6987-6999	β-parameters	_
48-12	7000-7003	for	_
48-13	7004-7016	participants	_
48-14	7017-7021	from	_
48-15	7022-7026	this	_
48-16	7027-7035	contrast	_
48-17	7036-7040	were	_
48-18	7041-7048	carried	_
48-19	7049-7056	forward	_
48-20	7057-7059	to	_
48-21	7060-7065	group	_
48-22	7066-7074	analyses	_
48-23	7075-7076	.	_

49-1	7077-7084	One-way	_
49-2	7085-7092	between	_
49-3	7093-7105	participants	_
49-4	7106-7111	ANOVA	_
49-5	7112-7115	was	_
49-6	7116-7125	conducted	_
49-7	7126-7128	at	_
49-8	7129-7132	the	_
49-9	7133-7144	whole-brain	_
49-10	7145-7150	level	_
49-11	7151-7153	to	_
49-12	7154-7161	compare	_
49-13	7162-7169	between	_
49-14	7170-7173	the	_
49-15	7174-7179	three	_
49-16	7180-7186	groups	_
49-17	7187-7188	.	_

50-1	7189-7192	The	_
50-2	7193-7200	one-way	_
50-3	7201-7206	ANOVA	_
50-4	7207-7211	only	_
50-5	7212-7222	identifies	_
50-6	7223-7230	regions	_
50-7	7231-7233	in	_
50-8	7234-7239	which	_
50-9	7240-7250	activation	_
50-10	7251-7253	is	_
50-11	7254-7263	different	_
50-12	7264-7271	between	_
50-13	7272-7278	groups	_
50-14	7279-7280	,	_
50-15	7281-7288	without	_
50-16	7289-7299	indicating	_
50-17	7300-7305	which	_
50-18	7306-7312	groups	_
50-19	7313-7318	drive	_
50-20	7319-7322	the	_
50-21	7323-7334	differences	_
50-22	7335-7337	or	_
50-23	7338-7341	the	_
50-24	7342-7356	directionality	_
50-25	7357-7359	of	_
50-26	7360-7363	the	_
50-27	7364-7375	differences	_
50-28	7376-7377	.	_

51-1	7378-7387	Therefore	_
51-2	7388-7389	,	_
51-3	7390-7393	for	_
51-4	7394-7402	clusters	_
51-5	7403-7405	in	_
51-6	7406-7411	which	_
51-7	7412-7415	the	_
51-8	7416-7421	ANOVA	_
51-9	7422-7431	indicated	_
51-10	7432-7437	group	_
51-11	7438-7449	differences	_
51-12	7450-7452	we	_
51-13	7453-7462	extracted	_
51-14	7463-7466	the	_
51-15	7467-7471	mean	_
51-16	7472-7481	parameter	_
51-17	7482-7491	estimates	_
51-18	7492-7495	for	_
51-19	7496-7500	each	_
51-20	7501-7508	subject	_
51-21	7509-7512	for	_
51-22	7513-7517	that	_
51-23	7518-7525	cluster	_
51-24	7526-7527	(	_
51-25	7528-7533	using	_
51-26	7534-7537	the	_
51-27	7538-7541	FSL	_
51-28	7542-7546	tool	_
51-29	7547-7556	Featquery	_
51-30	7557-7558	)	_
51-31	7559-7562	and	_
51-32	7563-7572	conducted	_
51-33	7573-7577	post	_
51-34	7578-7581	hoc	_
51-35	7582-7593	comparisons	_
51-36	7594-7600	across	_
51-37	7601-7607	groups	_
51-38	7608-7609	.	_

52-1	7610-7620	Regression	_
52-2	7621-7629	analyses	_
52-3	7630-7632	at	_
52-4	7633-7636	the	_
52-5	7637-7648	whole-brain	_
52-6	7649-7654	level	_
52-7	7655-7657	in	_
52-8	7658-7661	FSL	_
52-9	7662-7666	were	_
52-10	7667-7671	used	_
52-11	7672-7674	to	_
52-12	7675-7686	investigate	_
52-13	7687-7700	relationships	_
52-14	7701-7708	between	_
52-15	7709-7714	brain	_
52-16	7715-7725	activation	_
52-17	7726-7729	and	_
52-18	7730-7733	the	_
52-19	7734-7743	post-scan	_
52-20	7744-7754	subjective	_
52-21	7755-7762	ratings	_
52-22	7763-7765	of	_
52-23	7766-7776	motivation	_
52-24	7777-7780	and	_
52-25	7781-7789	pleasure	_
52-26	7790-7791	.	_

53-1	7792-7799	Imaging	_
53-2	7800-7811	comparisons	_
53-3	7812-7816	were	_
53-4	7817-7824	cluster	_
53-5	7825-7836	thresholded	_
53-6	7837-7842	using	_
53-7	7843-7846	the	_
53-8	7847-7850	FSL	_
53-9	7851-7855	tool	_
53-10	7856-7866	easythresh	_
53-11	7867-7868	,	_
53-12	7869-7874	using	_
53-13	7875-7876	a	_
53-14	7877-7888	family-wise	_
53-15	7889-7894	error	_
53-16	7895-7896	(	_
53-17	7897-7900	FWE	_
53-18	7901-7902	)	_
53-19	7903-7913	correction	_
53-20	7914-7916	at	_
53-21	7917-7918	p	_
53-22	7919-7920	<	_
53-23	7921-7925	0.05	_
53-24	7926-7927	(	_
53-25	7928-7935	initial	_
53-26	7936-7943	cluster	_
53-27	7944-7953	threshold	_
53-28	7954-7957	z=2	_
53-29	7958-7959	)	_
53-30	7960-7961	.	_

